[1] Fac Med, Observ Infarctus Cote Or, Lab Physiopathol & Pharmacol Cardiovasc Expt, F-21079 Dijon, France
来源:
ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
|
2004年
/
97卷
关键词:
D O I:
暂无
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Intravenous insulin therapy is used in diabetic patients at the acute phase of coronary syndrome (ACS). However. hyperglycemia in diabetic patients is a powerful predictive factor for patient outcome as it is associated with a doubling of in-hospital mortality and poor long-term prognosis. Recent studies involving non-diabetic patients show that even mild hyperglycemia in the setting of ACS is also a predictive factor of in-hospital mortality. Moreover. the new entity called impaired fasting glucose (IFG) (6.1 to 7 mmol/L) is not only an independent factor of mortality for coronary patients. but very recently has also been associated with a doubling of the risk of in-hospital mortality in the setting of ACS. Admission as well as follow-up glycaemia are fundamental parameters in ACS on the one hand for their prognostic value. and on the other end as a diagnostic tool in determining the presence of diabetes or IFG.